Rapamycin-Treated Mesenchymal Stem Cells for Immune Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for immune disorders rely heavily on drug-based immunosuppression, which are limited by side effects and inadequate long-term efficacy, with the mechanism of action of mesenchymal stem cells for immunomodulatory activity not fully understood and underresearched.
Innovation Solution
Development of rapamycin-treated mesenchymal stem cells expressing cell surface factors like CCR1, CCR2, CCR3, CCR4, CCR7, CCR9, and CXCR4, with increased expression of IDO, TGF-β, IL-10, and autophagic inducers, and decreased expression of mTOR signaling components, used as a cell therapy for immune disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If drug-based immunosuppression is used to treat immune disorders, then immune function is inhibited, but side effects occur and long-term efficacy is insufficient
Solution Approach 1:
The patent changes the therapeutic approach from chemical drugs to biologically modified cells. Mesenchymal stem cells are treated with rapamycin to modify their immunomodulatory parameters, specifically enhancing their ability to suppress immune responses through increased IDO expression and mTOR pathway inhibition, providing long-term efficacy without drug side effects
Solution Approach 2:
The patent uses rapamycin-treated mesenchymal stem cells as an intermediary between the immune system and therapeutic effect. These cells act as mediators that suppress immune responses through multiple mechanisms including IDO-mediated tryptophan depletion, TGF-β secretion, and IL-10 production, avoiding direct drug-toxicity interactions
2Reliability
If mesenchymal stem cells are used for immunomodulatory therapy, then therapeutic effect is achieved, but the mechanism of action is not fully understood and preparation of highly effective cells is limited
Solution Approach 1:
The patent systematically modifies key parameters of mesenchymal stem cells through rapamycin treatment, including upregulating IDO expression, enhancing TGF-β and IL-10 secretion, and inhibiting the mTOR signaling pathway. These parameter changes create a standardized preparation method for highly effective immunomodulatory cells with understood mechanisms
Solution Approach 2:
The patent establishes feedback mechanisms to monitor and optimize mesenchymal stem cell therapy. By measuring markers such as IDO expression levels, cytokine secretion profiles, and mTOR pathway activation, the treatment efficacy can be assessed and the cell preparation protocol refined to consistently produce therapeutically optimal cells
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The rapamycin-treated mesenchymal stem cells demonstrate enhanced immunomodulatory activity, effectively treating a range of immune disorders by promoting therapeutic effects and immune regulation, as shown in animal models for conditions such as osteoarthritis and inflammatory bowel disease.
Implementation Method 1
decreased expression of Phospho-mTOR, Rictor, and Ractor, which are signal transduction factors of mTOR, by the rapamycin treatment
Implementation Method 2
increased expression, in the mesenchymal stem cell, of any one or more autophagic inducers selected from the group consisting of Beclin1, ATG5, ATG7, LC3I, and LCII, by the rapamycin treatment
Implementation Method 3
increased expression of any one or more factors selected from the group consisting of indole 2,3-dioxygenase (IDO), transforming growth factor beta (TGF-β), and IL-10, by the rapamycin treatment
Data Source
AI summary
The present invention relates to a mesenchymal stem cell having immunomodulatory activity and a preparation method therefor and, more specifically, to: a rapamycin-treated mesenchymal stem cell having immunomodulatory activity, which expresses any one or more cell surface factors selected from the group consisting of CCR1, CCR2, CCR3, CCR4, CCR7, CCR9 and CXCR4; a cell therapy composition comprising the mesenchymal stem cell, for preventing or treating immune disorders; and a preparation method for the mesenchymal stem cell having immunomodulatory activity. The rapamycin-treated mesenchymal stem cell having immunomodulatory activity, according to the present invention, has increased expression of IDO, TGF-β and IL-10 which are factors having immunomodulatory activity, has decreased expression of Phospho-mTOR, Rictor and Ractor which are signal transduction factors of mTOR, and has increased expression, in the cell, of autophagic inducer Beclin1, ATG5, ATG7, LC3I or LCII. If this cell is used as a cell therapy in individuals having immune disorders, it is possible to effectively treat immune disorders.